Abbott (ABT) call put ratio 1.1 calls to 1 put into quarter results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
Abbott Labs (ABT) PT Raised to $140 at Evercore ISI
April 16, 2025 11:38 AM EDTEvercore ISI analyst Vijay Kumar raised the price target on Abbott Labs (NYSE: ABT) to $140.00 (from $138.00) while maintaining a Outperform rating.
The analyst comments "Thesis Update: In an environment where uncertainty is the dominating theme, ability to protect bottom-line should be appreciated.... More
Stifel Reiterates Buy Rating on Abbott Labs (ABT)
April 16, 2025 8:47 AM EDTStifel analyst Rick Wise reiterated a Buy rating and $135.00 price target on Abbott Labs (NYSE: ABT).
The analyst comments "From our perspective, Abbott's first quarter report contained few surprises, both to the upside or the downside. First quarter 2025 numbers came in largely in-line with our own projections and Consensus estimates. Reported sales at $10.36B (+6.9% y/y) were in-line with our $10.35B... More
BTIG Reiterates Buy Rating on Abbott Labs (ABT)
April 16, 2025 8:46 AM EDTBTIG analyst Marie Thibault reiterated a Buy rating and $140.00 price target on Abbott Labs (NYSE: ABT).
The analyst comments "With adj. EPS two cents above expectations despite a minor sales miss, we think this was a solid quarter from Abbott. We breathe a sigh of relief to see ABT reaffirm its 2025 guide for sales, adj. operating margin, and adj. EPS. We think this matters most to investors. The company reported Q1 total revenue $10.358B (+6.9 y/y org. and +4.0% y/y rep.) that was ~$50M below consensus of $10.407B. Results were helped... More
